Inosine.

Ribose feeds phosphoribosyl pyrophosphate, the sugar-phosphate that purine salvage uses to reattach bases such as hypoxanthine into nucleotides. Inosine supplies the base side and ribose the sugar side of the same reaction.

Two formyl transfer steps in de novo purine synthesis draw their one-carbon units from 10-formyl tetrahydrofolate, and the product of that route is inosine monophosphate.

Glycine is incorporated whole into the growing purine ring during inosine monophosphate synthesis, supplying two ring carbons and a nitrogen. It is a direct structural precursor.

Xanthine oxidoreductase carries a molybdenum cofactor and oxidises the hypoxanthine released from inosine onward to xanthine and urate. Molybdenum status governs the disposal route for an inosine dose.

Inosine is broken down to hypoxanthine and then to uric acid, while nicotinic acid competes with urate for renal tubular excretion. Dosing both raises the urate load from two directions.

Ascorbate has a mild uricosuric effect at the renal urate transporter, which runs counter to the urate that inosine catabolism generates. The two pull in opposite directions on the same handling step.

Part of the action attributed to inosine runs through adenosine A1 and A2A receptors, and caffeine is a competitive antagonist at exactly those receptors. Taken together each blunts that component of the other.

Xanthine oxidase, the enzyme that carries inosine's breakdown products through to uric acid, is a flavoprotein that holds FAD derived from riboflavin. Riboflavin supply is therefore part of how fast an inosine load is cleared down the purine catabolic route. Cofactor biochemistry, not a measured combination effect.

The same xanthine oxidase enzyme carries two iron-sulfur clusters alongside its molybdenum centre and FAD. Iron is structural in the protein rather than consumed by the reaction. The pairing is a cofactor relationship, not a dosing recommendation.

Glutamine donates nitrogen at several steps of de novo purine synthesis, the route that builds inosine monophosphate from scratch. Inosine supplied directly enters the same nucleotide pool from the salvage side instead. The two therefore feed one pool by different doors.

Quercetin inhibits xanthine oxidase in isolated-enzyme work, which would slow conversion of hypoxanthine and xanthine to urate. Combined with inosine, that means more of the purine load sits upstream of the enzyme for longer. This is in vitro enzymology, not a human outcome.

Inosine of bacterial origin has been reported as the active metabolite behind effects attributed to a Bifidobacterium strain in a preclinical model. That places gut bacteria as one source of the same molecule taken as a supplement. Preclinical and mechanistic; it is not human evidence for a combined effect.

Inulin is fermented by bifidobacteria, and bifidobacteria are among the organisms that release inosine and other purine nucleosides into the gut lumen. The chain from fibre to bacterial inosine is plausible and partly mapped, but the size of the contribution in a person is not established. Listed at Early for that reason.

GOS selectively feeds bifidobacteria, the same group linked to microbial inosine production. Any contribution to luminal inosine is indirect and has not been quantified in people. The mechanism is coherent, the magnitude is unknown.

Both inosine and nicotinamide riboside are ribosylated nucleosides carried across membranes by equilibrative and concentrative nucleoside transporters. Taken together at high amounts they draw on shared carriage. This is transporter pharmacology; no study has measured the interaction in people.

Butyrate and inosine both appear as microbial metabolites that shift together in gut metabolomic datasets. That is co-occurrence in measurements, not a demonstrated interaction. It is listed so the pairing is not mistaken for something stronger.

Inosine was historically stacked with creatine in sports formulas on the shared idea of supporting cellular energy handling. The pairing is a formulation habit with a plausible rationale rather than a tested combination. No combination trial supports an additive effect.